Nanjing Medlander Medical Technology (SH:688273)2024-09-23 08:41Group 1: Financial Performance - The company achieved operating revenue of 228 million yuan, representing a year-on-year growth of 11.73% [2] - The net profit attributable to shareholders reached 72.61 million yuan, with a year-on-year increase of 23.39% [2] - The net profit after deducting non-recurring gains and losses was 66.06 million yuan, showing a year-on-year growth of 32.81% [2] - Research and development investment amounted to 26.42 million yuan, accounting for 11.57% of the operating revenue [2] - As of June 30, 2024, total assets were 1.539 billion yuan, and net assets attributable to shareholders were 1.345 billion yuan [2] Group 2: Industry Context and Competitive Landscape - The overall industry remains competitive, with the company launching new products in the first quarter to address the competitive environment [3] - The company has established a supplier access system to ensure a stable supply chain and has built strategic partnerships with reputable upstream suppliers [3] - Cost control measures include maintaining mutually beneficial relationships with suppliers and strict budget management [3] Group 3: Market Insights and Future Outlook - The estimated consultation rate for pelvic floor treatment is currently at 13.4%, based on assumptions regarding the use of disposable electrodes [4] - Differences in data estimates arise from varying calculation bases and assumptions regarding the target populations for disposable electrode screenings [4] - The company emphasizes that the provided estimates are for reference and understanding, not commitments to future performance [4] Group 4: Risk Warning - Investors are advised to be cautious regarding investment risks, as the information provided does not constitute commitments or guarantees from the company regarding industry or performance forecasts [4]